Khaled Ali

Company: GlaxoSmithKline

Job title: Director

Seminars:

Panel Discussion: Shaping the Future of Treg Modulators to Produce Cutting-Edge Therapies 2:30 pm

Exploring novel Treg modulators beyond IL-2 (including IL-35 and TNFR-2 agonists) to uncover new therapeutic capabilities Investigating emerging small molecules and biologic modulators to supercharge therapeutic development Discovering antibody-specific Treg modulationRead more

day: Day 1 Treg Modulatorstrack